











10. Risinger JI, Chandramouli GV, Maxwell GL, et al. *Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.* Clin Cancer Res 2007;13:1713-9.
11. Kholmanskikh O, Lorient A, Brasseur F, De Plaen E, De Smet C. *Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.* Int J Cancer 2008;122:777-84.
12. Woloszynska-Read A, Zhang W, Yu J, et al. *Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.* Clin Cancer Res 2011;17:2170-80.
13. Smith IM, Glazer CA, Mithani SK, et al. *Coordinated activation of candidate proto-oncogenes and cancer testis antigens via promoter demethylation in head and neck cancer and lung cancer.* PLoS One 2009;4:e4961.
14. Fiorentino FP, Macaluso M, Miranda F, et al. *CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.* Mol Cancer Res 2011;9:225-33.
15. Bhan S, Negi SS, Shao C, et al. *BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.* Clin Cancer Res 2011;17:4267-76.
16. Okabayashi K, Fujita T, Miyazaki J, et al. *Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.* Cancer Sci 2012;103:1617-24.
17. Loukinov D, Ghochikyan A, Mkrtychyan M, et al. *Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.* J Cell Biochem 2006;98:1037-43.